DIAGNOSTIC VALUE OF TRF1 AND MMP-7 AGAINST VARIOUS PROSTATE NEOPLASMS

Cover Page

Cite item

Full Text

Abstract

 The authors analyzed the relative levels of telomeric repeat-binding protein factor 1 (TRF1) and matrix metalloproteinase-7 (MMR-7) mRNA expression by the cells obtained from prostate biopsy specimens of patients with benign prostate hyperplasia and cancer (PC) and healthy men without visible prostate diseases and calculated a TRF1/MMR-7 expression ratio for the above conditions. There was a statistically significant difference in the levels of TRF1 and MMP-7 expression and TRF1/MMP-7 ratio in the study groups, which may be suggestive of the high diagnostic value of these markers in determining the early-stage of PC and which enables clinicians to make a more accurate diagnosis in patients with various urologic diseases.

About the authors

V. P. Avdoshin

Department of Urology and Surgical Nephrology, Russian Peoples Friendship University, Moscow

Email: apryatin@mail.ru
Кафедра урологии и оперативной нефрологии Russian Federation

S. A. Apryatin

Moscow Research Institute of Medical Ecology, Moscow Department of Healthcare

Author for correspondence.
Email: apryatin@mail.ru
Russian Federation

S. A. Pulbere

Department of Urology and Surgical Nephrology, Russian Peoples Friendship University, Moscow

Email: apryatin@mail.ru
Russian Federation

S. A. Gordeev

Moscow Research Institute of Medical Ecology, Moscow Department of Healthcare

Email: apryatin@mail.ru
Russian Federation

A. I. Glukhov

Moscow Research Institute of Medical Ecology, Moscow Department of Healthcare

Department of Biochemistry, I.M. Sechenov Moscow State Medical University

Email: apryatin@mail.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36986 от  21.07.2009.